Oral praziquantel kinetics in normal and Schistosoma haematobium-infected subjects.
The kinetics of praziquantel was studied in normal and Schistosoma haematobium-infected Ghanaian subjects. There was a wide interindividual variation in half-life (t1/2), Cmax, Tmax, area under the curve (AUC) (0-8 h), and urinary recovery. No differences were noted between the two groups with regard to Tmax, AUC (0-8 h), and t1/2. Mean Cmax was higher in the patients than in the control subjects. The 8-hr urinary recovery of praziquantel was higher in the subjects with urinary schistosomiasis. The amount of praziquantel excreted unchanged in urine was 0.0052 +/- 0.0027% (SD) of the dose for the control subjects and 0.0054 +/- 0.0027% (SD) for the patients.
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D006207:Half-Life; D006801:Humans; D011223:Praziquantel / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D012553:Schistosomiasis haematobia / Q000188:drug therapy* / Q000652:urine
D011223:Praziquantel